DOCSLIB.ORG

P53 Prevents Neurodegeneration by Regulating Synaptic Genes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
P53 Prevents Neurodegeneration by Regulating Synaptic Genes p53 prevents neurodegeneration by regulating synaptic genes Paola Merloa, Bess Frosta, Shouyong Pengb,c, Yawei J. Yangd,e,f, Peter J. Parkc,g, and Mel Feanya,1 Departments of aPathology and cMedicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115; bDepartment of Medical Oncology, Dana–Farber Cancer Institute, Boston, MA 02115; dDivision of Genetics and Manton Center for Orphan Disease Research, Children’s Hospital Boston, Boston, MA 02115; eBroad Institute of MIT and Harvard, fHoward Hughes Medical Institute, Cambridge, MA 02142; and gCenter for Biomedical Informatics, Harvard Medical School, Boston, MA 02115 Edited by Nancy M. Bonini, University of Pennsylvania, Philadelphia, PA, and approved October 30, 2014 (received for review October 8, 2014) DNA damage has been implicated in neurodegenerative disorders, Here we show that p53 is neuroprotective in an in vivo model including Alzheimer’s disease and other tauopathies, but the con- of tauopathy. Through chromatin immunoprecipitation (ChIP)- sequences of genotoxic stress to postmitotic neurons are poorly chip analyses we determine that p53 controls the transcription of understood. Here we demonstrate that p53, a key mediator of the a group of genes involved in synaptic function. Genetic manipu- DNA damage response, plays a neuroprotective role in a Drosophila lation of these genes modifies tau neurotoxicity. We find that the model of tauopathy. Further, through a whole-genome ChIP-chip transcriptional control by p53 of these synaptic genes is conserved analysis, we identify genes controlled by p53 in postmitotic neu- in murine neurons and human brain. Our results thus implicate rons. We genetically validate a specific pathway, synaptic function, synaptic function as a critical p53 target in neuroprotection. in p53-mediated neuroprotection. We then demonstrate that the control of synaptic genes by p53 is conserved in mammals. Collec- Results tively, our results implicate synaptic function as a central target in p53 Protects from Neurodegeneration During Aging in Vivo. To in- p53-dependent protection from neurodegeneration. vestigate the role of p53 in tauopathy pathogenesis, we first expressed tau in flies lacking p53 (Fig. 1A). Although p53-null p53 transcriptional function | ChIP-chip | neurodegeneration | tauopathy | flies showed no evidence of neurodegeneration in the absence of synaptic genes transgenic human tau (Fig. 1 B–D), cell death, as measured by the number of TUNEL-positive neurons, significantly increased 11-1B-1 eurodegenerative diseases are a group of inexorably pro- in the brains of tau-expressing, p53 (p53 )-null animals Ngressive disorders characterized by ongoing dysfunction and compared with tau-transgenic animals with normal levels of en- death of postmitotic neurons and are among the principal causes of dogenous p53 (Fig. 1B and Fig. S1A, Left). Neurodegeneration in morbidity and mortality associated with aging (1–3). Tauopathies, our model, as in mouse tauopathy models and in Alzheimer’s including Alzheimer’s disease, are defined neuropathologically by disease, is associated with abnormal reactivation of the cell cycle aggregation and deposition of the microtubule-associated protein in postmitotic neurons (Fig. S1B) (5, 6, 14, 15). Removing p53 tau accompanying neuronal loss (1–3). DNA damage has been from tau-transgenic flies significantly increased cell-cycle reac- NEUROSCIENCE documented in neurodegenerative disorders, including tauopathies, tivation, as measured by proliferating cell nuclear antigen but the effects of DNA damage on the function and viability of (PCNA) reexpression in neurons (Fig. 1C and Fig. S1A, Right). nondividing neurons are poorly understood (4–6). Enhancement of human tau-driven neuronal death and cell-cycle reactivation was also observed when a second p53 null allele In this study, we used a Drosophila model of tauopathy based 5A-1-4 on expression of human tau carrying the R406W mutation, which (p53 ; Fig. S1 C and D) was used to remove p53 function. To is found in patients with the familial tauopathy frontotemporal dementia with Parkinsonism linked to chromosome 17 (7). Our Significance model recapitulates several key features of human tauopathies, including accumulation of abnormally phosphorylated and con- The transcription factor p53 plays a critical role in the cellular formationally altered tau, age-dependent neurodegeneration, response to DNA damage and has thus been studied in- and early death (7). We have previously shown that expression of tensively in oncogenesis research. However, the role that p53 human tau in Drosophila neurons induces the DNA damage plays in the response of postmitotic neurons to cellular stress response, including p53 up-regulation, and that reducing the has received less attention. Here we describe an unexpected function of the DNA damage checkpoint significantly increases neuroprotective role for p53 in an in vivo model of tau-medi- neurodegeneration (5). These data suggest an unexpected neu- ated neurodegeneration relevant to Alzheimer’s disease and roprotective role for p53 in postmitotic neurons. We were related disorders. Further, we identify synaptic function as therefore motivated to examine the transcriptional function of a novel target pathway for p53 in aging neurons, consistent p53 in the context of progressive neurodegeneration. with the growing evidence for synaptic pathology as an early p53, together with p63 and p73, comprises a family of tran- event in neurodegenerative disease. Our study defines mech- scription factors, which regulate fundamental processes including anistically a new, conserved role for p53 in protecting post- proliferation, differentiation, senescence, and cell death (8, 9). The mitotic neurons from degeneration during aging and disease. p53 family has been extensively studied in tumorigenesis, but the Author contributions: P.M. and M.F. designed research; P.M., B.F., Y.J.Y., and M.F. per- role of family members in postmitotic neurons is poorly defined, formed research; P.M. contributed new reagents/analytic tools; P.M., S.P., P.J.P., and M.F. with an emerging body of literature suggesting involvement of the analyzed data; and P.M. and M.F. wrote the paper. p73 subfamily in aspects of neuronal development and neuro- The authors declare no conflict of interest. – degeneration (10 12). Using Drosophila to study p53-dependent This article is a PNAS Direct Submission. transcription in neurodegeneration has two significant advantages. Data deposition: The data reported in this paper have been deposited in the Gene Ex- First, transcription can be studied in aging neurons in vivo. Second, pression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE40418). analysis of overall p53 family function in a simplified genome, 1To whom correspondence should be addressed. Email: [email protected]. “ ” which contains a single p53 gene, may reveal ancestral activities This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. of the family (9, 13). 1073/pnas.1419083111/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1419083111 PNAS | December 16, 2014 | vol. 111 | no. 50 | 18055–18060 Downloaded by guest on September 26, 2021 AB with p53 if they had binding peaks in the promoter region, de- fined as 2 kb upstream and 1 kb downstream of the annotated transcriptional start site. Examination of the ChIP-chip data 60 *** ctr p53 nulltau tau + p53 null 50 revealed that p53 binds the promoter region of ∼1,500 genes in ∼ a-tau 40 tau-transgenic flies, of which 550 showed significant enrich- 30 ment in tau-expressing neurons compared with controls [false a-actin 20 discovery rate (FDR) < 0.01; Fig. 2B]. To provide a compre- 10 hensive picture of p53 transcriptional function in postmitotic p53 wt # TUNEL positive cells TUNEL # 0 neurons, we included the entire list of 1,500 genes bound in tau- p53 mut ctr p53 null tau tau + transgenic animals in our subsequent analyses (Dataset S1). p53 null An important physiological role for the p53 targets we iden- CD tified here is consistent with our previous recovery of th, par-1, 120 *** 35 *** Tao, cdi, chb, aop, dally, and Fmr1 in an unbiased forward genetic 100 30 screen for modifiers of tau neurotoxicity (19). Each of these 80 25 genes was bound by p53 in the present ChIP-chip experiment. 60 20 Similarly, a number of the genes that we have previously shown 15 *** 40 10 to control tau neurotoxicity in pathway-focused studies are also # PCNA foci # PCNA 20 (cm / 30 sec) walking speed 5 p53 targets: hep, Act5C, Drp1, sqh, WASp, zip, PHGPx, CycD,and 0 0 eIF-4E (5, 6, 20–22). In addition, the list of genes bound by p53 ctr p53 null tau tau + ctr p53 null tau tau + in our ChIP-chip experiment includes cell-cycle regulators (p53, p53 null p53 null Gadd45, CycD, Cdt1, and Msh2). Recovery of these cell-cycle genes is consistent with genetic evidence supporting a neuro- Fig. 1. p53 is neuroprotective in Drosophila tauopathy. (A, Upper) Tau protein levels do not change in p53-null flies. (Lower) Genomic PCR analysis protective, rather than proapoptotic, role for the DNA damage confirms genotypes at the p53 locus for the animals used. (B) Apoptosis, checkpoint in postmitotic neurons (5, 6). Of note, vertebrate indicated by TUNEL-positive neurons, increases in the brains of tau-trans- homologs of p53, Gadd45, CycD, Cdt1, and Msh2 are known p53 genic, p53-null animals. (C) Cell-cycle reactivation, indicated by PCNA-posi- targets, supporting conservation of p53 binding and function tive foci, increases in the brains of tau-transgenic, p53-null animals. In B and from flies to mammals (18, 23, 24). C, flies are 10-d-old (n ≥ 6 per genotype). (D) Removing p53 in tau-transgenic We next determined whether particular cellular pathways were animals worsens locomotion, measured as walking speed. Flies are 2-d-old enriched for p53 binding. We used the list of p53 target genes (n = 18 per genotype). In the graph, values represent mean ± SEM. Asterisks indicate significant differences compared with control by ANOVA with Student–Newman–Keuls post hoc test for multiple comparisons.
Load more

Recommended publications
  • Mutant P53 Protects Cells from 12-O-Tetradecanoylphorbol-13- Acetate–Induced Death by Attenuatingactivating Transcription Factor 3 Induction
    Research Article Mutant p53 Protects Cells from 12-O-Tetradecanoylphorbol-13- Acetate–Induced Death by AttenuatingActivating Transcription Factor 3 Induction Yosef Buganim,1 Eyal Kalo,1 Ran Brosh,1 Hila Besserglick,1 Ido Nachmany,3 Yoach Rais,2 Perry Stambolsky,1 Xiaohu Tang,1 Michael Milyavsky,1 Igor Shats,1 Marina Kalis,1 Naomi Goldfinger,1 and Varda Rotter1 1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; 2Department of Life Science, Bar-Ilan University, Ramat Gan, Israel; and 3Department of General Surgery B, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel Abstract mutated. Notably, the predominant mode of p53 inactivation is by Mutations in p53 are ubiquitous in human tumors. Some p53 point mutation rather than by deletion or truncation. These data mutations not only result in loss of wild-type (WT) activity but coupled with the observation that mutant p53 is generally highly also grant additional functions, termed ‘‘gain of function.’’ overexpressed in tumors have led to the hypothesis that mutant In this study, we explore how the status of p53 affects the p53 possesses gain-of-function activities. This hypothesis is immediate response gene activating transcription factor 3 supported by the results of in vivo and in vitro studies. For (ATF3) in the 12-O-tetradecanoylphorbol-13-acetate (TPA)- example, mice harboring mutant p53 display allele-specific tumor protein kinase C (PKC) pathway. We show that high doses of spectra, higher metastatic frequency, enhanced cell proliferation, TPA induce ATF3 in a WT p53-independent manner correlat- and higher transformation potential compared with their p53-null ingwith PKCs depletion and cell death.
    [Show full text]
  • Action on Muscle Metabolism and Insulin Sensitivity E Strong Enough for a Man, Made for a Woman
    Review The impact of ERa action on muscle metabolism and insulin sensitivity e Strong enough for a man, made for a woman Andrea L. Hevener*, Zhenqi Zhou, Timothy M. Moore, Brian G. Drew, Vicent Ribas ABSTRACT Background: The incidence of chronic disease is elevated in women after menopause. Natural variation in muscle expression of the estrogen receptor (ER)a is inversely associated with plasma insulin and adiposity. Moreover, reduced muscle ERa expression levels are observed in women and animals presenting clinical features of the metabolic syndrome (MetSyn). Considering that metabolic dysfunction impacts nearly a quarter of the U.S. adult population and elevates chronic disease risk including type 2 diabetes, heart disease, and certain cancers, treatment strategies to combat metabolic dysfunction and associated pathologies are desperately needed. Scope of the review: This review will provide evidence supporting a critical and protective role for skeletal muscle ERa in the regulation of metabolic homeostasis and insulin sensitivity, and propose novel ERa targets involved in the maintenance of metabolic health. Major conclusions: Studies identifying ERa-regulated pathways essential for disease prevention will lay the important foundation for the rational design of novel therapeutics to improve the metabolic health of women while limiting secondary complications that have plagued traditional hormone replacement interventions. Ó 2018 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Keywords Estrogen action; Estrogen receptors; Insulin sensitivity; Metabolic homeostasis 1. INTRODUCTION new-onset T2DM in postmenopausal women following HRT compared with placebo [7]. The mechanism by which HRT reduces T2D incidence For over two decades researchers have shown strong relationships in postmenopausal women is not yet known however molecular between estrogen action and metabolic health in women.
    [Show full text]
  • An Autoregulatory Loop Controls Peroxisome Proliferator-Activated Receptor Γ Coactivator 1Α Expression in Muscle
    Institutional Repository of the University of Basel University Library Schoenbeinstrasse 18-20 CH-4056 Basel, Switzerland http://edoc.unibas.ch/ Year: 2003 An autoregulatory loop controls peroxisome proliferator-activated receptor γ coactivator 1α expression in muscle Handschin, C. and Rhee, J. and Lin, J. and Tarr, P. T. and Spiegelman, B. M. Posted at edoc, University of Basel Official URL: http://edoc.unibas.ch/dok/A5258732 Originally published as: Handschin, C. and Rhee, J. and Lin, J. and Tarr, P. T. and Spiegelman, B. M.. (2003) An autoregulatory loop controls peroxisome proliferator-activated receptor γ coactivator 1α expression in muscle. Proceedings of the National Academy of Sciences of the United States of America, Vol. 100, H. 12. S. 7111-7116. An Autoregulatory Loop Controls PGC-1 Expression in Muscle Christoph Handschin, James Rhee, Jiandie Lin, Paul T. Tarr, and Bruce M. Spiegelman* Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115 Published in Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7111-6. PMID: 12764228. doi: 10.1073/pnas.1232352100 Copyright © National Academy of Sciences; Proceedings of the National Academy of Sciences USA Page 1 of 24 Classification: Biological Sciences, Cell Biology An Autoregulatory Loop Controls PGC-1 Expression in Muscle Christoph Handschin, James Rhee, Jiandie Lin, Paul T. Tarr, and Bruce M. Spiegelman* Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115 * To whom
    [Show full text]
  • Global Mef2 Target Gene Analysis in Skeletal and Cardiac Muscle
    GLOBAL MEF2 TARGET GENE ANALYSIS IN SKELETAL AND CARDIAC MUSCLE STEPHANIE ELIZABETH WALES A DISSERTATION SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY GRADUATE PROGRAM IN BIOLOGY YORK UNIVERSITY TORONTO, ONTARIO FEBRUARY 2016 © Stephanie Wales 2016 ABSTRACT A loss of muscle mass or function occurs in many genetic and acquired pathologies such as heart disease, sarcopenia and cachexia which are predominantly found among the rapidly increasing elderly population. Developing effective treatments relies on understanding the genetic networks that control these disease pathways. Transcription factors occupy an essential position as regulators of gene expression. Myocyte enhancer factor 2 (MEF2) is an important transcription factor in striated muscle development in the embryo, skeletal muscle maintenance in the adult and cardiomyocyte survival and hypertrophy in the progression to heart failure. We sought to identify common MEF2 target genes in these two types of striated muscles using chromatin immunoprecipitation and next generation sequencing (ChIP-seq) and transcriptome profiling (RNA-seq). Using a cell culture model of skeletal muscle (C2C12) and primary cardiomyocytes we found 294 common MEF2A binding sites within both cell types. Individually MEF2A was recruited to approximately 2700 and 1600 DNA sequences in skeletal and cardiac muscle, respectively. Two genes were chosen for further study: DUSP6 and Hspb7. DUSP6, an ERK1/2 specific phosphatase, was negatively regulated by MEF2 in a p38MAPK dependent manner in striated muscle. Furthermore siRNA mediated gene silencing showed that MEF2D in particular was responsible for repressing DUSP6 during C2C12 myoblast differentiation. Using a p38 pharmacological inhibitor (SB 203580) we observed that MEF2D must be phosphorylated by p38 to repress DUSP6.
    [Show full text]
  • The Impact of Skeletal Muscle Erα on Mitochondrial Function And
    Copyedited by: oup MINI REVIEW The Impact of Skeletal Muscle ERα on Mitochondrial Function and Metabolic Health Downloaded from https://academic.oup.com/endo/article-abstract/161/2/bqz017/5735479 by University of Southern California user on 19 February 2020 Andrea L. Hevener1,2, Vicent Ribas1, Timothy M. Moore1, and Zhenqi Zhou1 1David Geffen School of Medicine, Department of Medicine, Division of Endocrinology, Diabetes, and Hypertension, University of California, Los Angeles, California 90095; and 2Iris Cantor-UCLA Women’s Health Research Center, University of California, Los Angeles, California 90095 ORCiD numbers: 0000-0003-1508-4377 (A. L. Hevener). The incidence of chronic disease is elevated in women after menopause. Increased expression of ESR1 (the gene that encodes the estrogen receptor alpha, ERα) in muscle is highly associated with metabolic health and insulin sensitivity. Moreover, reduced muscle expression levels of ESR1 are observed in women, men, and animals presenting clinical features of the metabolic syndrome (MetSyn). Considering that metabolic dysfunction elevates chronic disease risk, including type 2 diabetes, heart disease, and certain cancers, treatment strategies to combat metabolic dysfunction and associated pathologies are desperately needed. This review will provide published work supporting a critical and protective role for skeletal muscle ERα in the regulation of mitochondrial function, metabolic homeostasis, and insulin action. We will provide evidence that muscle-selective targeting of ERα may be effective for the preservation of mitochondrial and metabolic health. Collectively published findings support a compelling role for ERα in the control of muscle metabolism via its regulation of mitochondrial function and quality control. Studies identifying ERα-regulated pathways essential for disease prevention will lay the important foundation for the design of novel therapeutics to improve metabolic health of women while limiting secondary complications that have historically plagued traditional hormone replacement interventions.
    [Show full text]
  • The Repression of MEF2 Transcription Factors Exerted by Class Iia Hdacs
    81,9(56,7<2)8',1( BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB 3K'Course in Biomedical Sciences and Biotechnology ;;9,,&<&/( THE REPRESSION OF MEF2 TRANSCRIPTION FACTORS EXERTED BY CLASS IIA HDACS AND THEIR DEGRADATION STIMULATED BY CDK4 DETERMINE THE ACQUISITION OF HALLMARKS OF TRANSFORMATION IN FIBROBLASTS. 3K'6WXGHQW'L*LRUJLR(URV 7XWRUSURI&ODXGLR%UDQFROLQL (URV'L*LRUJLR To my family, Sara and those who believe in the research against cancer ABSTRACT 1 RIASSUNTO 2 INTRODUCTION 3 1. The HDACs world 3 2. Class IIa HDACs: similarities and differences between class IIa and class I HDACs 4 3. Class IIa HDACs: HDACs with orphan substrates or missed during evolution? 7 4. Pathways of regulation 10 a) regulation of class IIa HDACs transcription and modulation of the stability of the messengers (RNAi) 10 b) sub-cellular localization 11 5. Partners and biological functions 20 6. Class IIa HDACs as regulators of proliferation and cancer 28 7. MEF2 family of transcription factors 37 8. On the molecular basis of the MEF2-Class IIa HDACs axis: structure of MEF2/DNA, MEF2/Cabin1/DNA, MEF2/HDAC9/DNA and MEF2/DNA/p300 complexes. 38 9. Pathways of regulation 40 a) binding to repressors and co-activators 41 b) post-translational modifications 42 c) regulation of MEF2s transcription and modulation of the stability of the messengers (RNAi) 49 d) regulation of protein stability 51 10. Main functional roles 53 11. MEF2 as a regulator of differentiation programs 54 12. A lesson from the study of the knock-outs. 56 The role of MEF2s and of the MEF2-class IIa HDACs axis in myogenesis 57 The role of MEF2 TFs in cardiomyogenesis 59 The role of MEF2 TFs and of the MEF2-class IIa HDACs axis in endochondral bone ossification 59 The role of MEF2s and of the MEF2-class IIa HDACs axis in vasculogenesis and differentiation of vascular smooth muscle cells 60 The role of MEF2 TFs in neuronal development 60 The role of MEF2s in hematopoiesis and T cell development 61 The role of MEF2s in melanogenesis 62 The role of MEF2s in neural crest development 62 1.
    [Show full text]
  • The Function of the MEF2 Family of Transcription Factors in Cardiac Development, Cardiogenomics, and Direct Reprogramming
    Journal of Cardiovascular Development and Disease Review The Function of the MEF2 Family of Transcription Factors in Cardiac Development, Cardiogenomics, and Direct Reprogramming Cody A. Desjardins and Francisco J. Naya * Department of Biology, Program in Cell and Molecular Biology, Boston University, 24 Cummington Mall Boston, Boston, MA 02215, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-617-353-2469; Fax: +1-617-353-6340 Academic Editors: Sean M. Wu and Neil C. Chi Received: 5 June 2016; Accepted: 8 August 2016; Published: 11 August 2016 Abstract: Proper formation of the mammalian heart requires precise spatiotemporal transcriptional regulation of gene programs in cardiomyocytes. Sophisticated regulatory networks have evolved to not only integrate the activities of distinct transcription factors to control tissue-specific gene programs but also, in many instances, to incorporate multiple members within these transcription factor families to ensure accuracy and specificity in the system. Unsurprisingly, perturbations in this elaborate transcriptional circuitry can lead to severe cardiac abnormalities. Myocyte enhancer factor–2 (MEF2) transcription factor belongs to the evolutionarily conserved cardiac gene regulatory network. Given its central role in muscle gene regulation and its evolutionary conservation, MEF2 is considered one of only a few core cardiac transcription factors. In addition to its firmly established role as a differentiation factor, MEF2 regulates wide variety of, sometimes antagonistic, cellular processes such as cell survival and death. Vertebrate genomes encode multiple MEF2 family members thereby expanding the transcriptional potential of this core transcription factor in the heart. This review highlights the requirement of the MEF2 family and their orthologs in cardiac development in diverse animal model systems.
    [Show full text]
  • The Nuclear Receptor Pparb/D Programs Muscle Glucose Metabolism in Cooperation with AMPK and MEF2
    Downloaded from genesdev.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press The nuclear receptor PPARb/d programs muscle glucose metabolism in cooperation with AMPK and MEF2 Zhenji Gan,1,3 Eileen M. Burkart-Hartman,2,3,4 Dong-Ho Han,2 Brian Finck,2 Teresa C. Leone,1,2 Emily Y. Smith,1 Julio E. Ayala,1 John Holloszy,2 and Daniel P. Kelly1,2,5 1Diabetes and Obesity Research Center, Sanford-Burnham Medical Research Institute, Orlando, Florida 32827, USA: 2Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA To identify new gene regulatory pathways controlling skeletal muscle energy metabolism, comparative studies were conducted on muscle-specific transgenic mouse lines expressing the nuclear receptors peroxisome proliferator-activated receptor a (PPARa; muscle creatine kinase [MCK]-PPARa)orPPARb/d (MCK-PPARb/d). MCK-PPARb/d mice are known to have enhanced exercise performance, whereas MCK-PPARa mice perform at low levels. Transcriptional profiling revealed that the lactate dehydrogenase b (Ldhb)/Ldha gene expression ratio is increased in MCK-PPARb/d muscle, an isoenzyme shift that diverts pyruvate into the mitochondrion for the final steps of glucose oxidation. PPARb/d gain- and loss-of-function studies in skeletal myotubes demonstrated that PPARb/d, but not PPARa, interacts with the exercise-inducible kinase AMP-activated protein kinase (AMPK) to synergistically activate Ldhb gene transcription by cooperating with myocyte enhancer factor 2A (MEF2A) in aPPARb/d ligand-independent manner. MCK-PPARb/d muscle was shown to have high glycogen stores, increased levels of GLUT4, and augmented capacity for mitochondrial pyruvate oxidation, suggesting a broad reprogram- ming of glucose utilization pathways.
    [Show full text]
  • The Role of Gata2 in Hematopoietic and Vascular Development By
    The Role of Gata2 in Hematopoietic and Vascular Development by William D Brandt A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Cellular and Molecular Biology) in The University of Michigan 2009 Doctoral Committee: Professor James Douglas Engel, Chair Professor Eric R Fearon Professor Deborah L Gumucio Associate Professor Thomas M Glaser William D Brandt 2009 Dedication To my family, without whom this PhD would never have been possible. ii Acknowledgements The Engel lab and the University of Michigan will always have my deepest gratitude, particularly the lab’s proprietor and my thesis advisor Doug Engel, whose love of science and good nature has always been a source of inspiration. Doug has been instrumental in my growth as a nascent scientist and I will forever be indebted to him. My gratitude also goes to Kim-Chew Lim and Tomo Hosoya, whose wealth of knowledge and support were relied upon regularly. To Deb Gumucio, Tom Glaser, and Eric Fearon, whose advice and support facilitated my maturation from a naïve student to a proficient scientist – thank you. And to Lori Longeway and Kristin Hug, whose capabilities as department representatives I repeatedly put to the test; you came through for me every time. Thank you. Finally, no amount of words can express how truly grateful and indebted I am to my parents and sister – Cary, Kim, and Jenelle. I would not be in this position today without their unerring love and support. iii Table of Contents Dedication ii Acknowledgements iii List of Figures v List of Tables vi Abstract vii Chapter 1.
    [Show full text]
  • (PGC-1 ) and Mitochondrial Function by MEF2 and HDAC5
    Regulation of peroxisome proliferator-activated receptor ␥ coactivator 1␣ (PGC-1␣) and mitochondrial function by MEF2 and HDAC5 Michael P. Czubryt*, John McAnally*, Glenn I. Fishman†, and Eric N. Olson*‡ *Department of Molecular Biology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-9148; and †Division of Cardiology, New York University School of Medicine, 550 First Avenue, OBV-A615, New York, NY 10016 Contributed by Eric N. Olson, December 13, 2002 The myocyte enhancer factor-2 (MEF2) transcription factor regu- To further investigate the importance of HDAC5 in cardiac lates muscle development and calcium-dependent gene expres- function, we generated transgenic mice harboring a doxycycline sion. MEF2 activity is repressed by class II histone deacetylases (DOX)-inducible cardiac-specific transgene encoding the (HDACs), which dissociate from MEF2 when phosphorylated on HDAC5S͞A signal-resistant mutant. Because this mutant is able two serine residues in response to calcium signaling. To explore the to efficiently inhibit MEF2 transactivation (4), we hypothesized potential importance of MEF2͞HDAC interactions in the heart, we that it would allow us to more clearly identify MEF2͞HDAC generated transgenic mice expressing a signal-resistant form of targets free from complications of unknown kinases and phos- HDAC5 under cardiac-specific and doxycycline-inducible regula- phatases that may alter the activity of endogenous HDAC5. tion. Transgene expression resulted in sudden death in male mice Expression of HDAC5S͞A in the adult heart resulted in sudden accompanied by loss and morphologic changes of cardiac mito- death of male mice accompanied by gross aberrations in mito- chondria and down-regulation of mitochondrial enzymes.
    [Show full text]
  • MEF2 and the Right Ventricle: from Development to Disease
    REVIEW published: 28 March 2019 doi: 10.3389/fcvm.2019.00029 MEF2 and the Right Ventricle: From Development to Disease Katharine R. Clapham 1†, Inderjit Singh 2†, Isabella S. Capuano 1,3, Sudarshan Rajagopal 4 and Hyung J. Chun 1* 1 Section of Cardiovascular Medicine, Department of Internal Medicine, Yale Cardiovascular Research Center, Yale School of Medicine, New Haven, CT, United States, 2 Section of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States, 3 Choate Rosemary Hall, Wallingford, CT, United States, 4 Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC, United States Pulmonary arterial hypertension is a progressive and ultimately life-limiting disease in which survival is closely linked to right ventricular function. The right ventricle remains relatively understudied, as it is known to have key developmental and structural differences from the left ventricle. Here, we will highlight what is known about the right ventricle in normal physiology and in the disease state of pulmonary arterial hypertension. Specifically, we will explore the role of the family of MEF2 (myocyte enhancer factor 2) transcription factors in right ventricular development, its response to increased afterload, and in the endothelial dysfunction that characterizes pulmonary arterial hypertension. Finally, we will turn to review potentially novel therapeutic strategies Edited by: targeting these pathways. Susumu Minamisawa, Jikei University School of Medicine, Keywords: right ventricle, MEF2, pulmonary hypertension, HDAC, hypertrophy Japan Reviewed by: Yibin Wang, INTRODUCTION University of California, Los Angeles, United States Pulmonary arterial hypertension (PAH) remains a significant therapeutic challenge, despite Isao Shiraishi, ongoing advances in our body of knowledge of this devastating disease.
    [Show full text]
  • Cis-Regulatory Differences Explaining Evolved Levels of Endometrial Invasibility in Eutherian Mammals
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.04.283366; this version posted September 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Cis-Regulatory Differences Explaining Evolved Levels of Endometrial Invasibility in Eutherian Mammals Yasir Suhail1,3, Jamie D. Maziarz2,3, Anasuya Dighe 2,3 , Gunter Wagner2,3,5,6,*, Kshitiz1,3,4,* 1 Department of Biomedical Engineering, University of Connecticut Health, Farmington, CT 2. Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT 3. Cancer Systems Biology Center (CaSB@Yale), Yale University, West Haven, CT 4. Center for Cell Analysis and Modeling, University of Connecticut Health, Farmington, CT 4. Department of Obstetrics, Gynecology and Reproductive Sciences, Yale Medical School, New Haven, CT 5. Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI * Corresponding Authors: [email protected], [email protected] Abstract Eutherian (placental) mammals exhibit great differences in the degree of placental invasion into the maternal endometrium, with humans being on the most invasive end. Previously, we have shown that these differences in invasiveness is largely controlled by the stromal fibroblasts of the maternal endometrium, with secondary effect on stroma of other tissues resulting in correlated differences in cancer malignancy. Here, we present a statistical investigation of the second dogma linking the phenotypic and transcriptional differences to the genomic changes across species, revealing the regulatory genomic sequence differences underlying these inter-species differences.
    [Show full text]